Huntsman CORP
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $HUN in the last 30 days.
See all $HUN insider activity →Analysts from Mizuho and Citi maintained Hold ratings on Huntsman (HUN) with $11.00 price targets. Exxon Mobil (XOM) received a Buy rating and $185.00 target from UBS, while Barclays also recommended Buy with a $177.00 target. HUN closed at $9.05, XOM at $158.71.
Huntsman and Olin told Brazil's CADE that their proposed transaction does not overlap in agricultural inputs, responding to a query from the authority. The query was prompted by the companies' broad business-activity classification.
Olin (OLN) and Huntsman (HUN) cleared a U.S. antitrust hurdle for their all-stock merger, expected to create a $12.5B chemicals company with $400M in cost synergies. The deal, targeting 1H 2027 completion, still needs regulatory approvals. OLN shares fell 32.2% and HUN dropped 8.6% over the past year.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning HUN (Huntsman CORP). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent HUN coverage spans mergers & acquisitions and financial news.
Analyst maintains Hold, suggesting limited upside.
Regulatory clarification may smooth approval of Huntsman's pending merger with Olin.
Regulatory clearance reduces deal uncertainty and improves merger probability.
Deal momentum increases, supporting HUN share price.
Clearing the antitrust hurdle removes a major risk, likely boosting investor sentiment toward the combined entity.
AlphAI scores every news story that mentions HUN with an AI model for sentiment and relevance, and aggregates insider trades from Huntsman CORP's SEC EDGAR Form 4 filings. Figures refresh continuously.
Analysts from Mizuho and Citi maintained Hold ratings on Huntsman (HUN) with $11.00 price targets. Exxon Mobil (XOM) received a Buy rating and $185.00 target from UBS, while Barclays also recommended Buy with a $177.00 target. HUN closed at $9.05, XOM at $158.71.
2 min readHuntsman and Olin told Brazil's CADE that their proposed transaction does not overlap in agricultural inputs, responding to a query from the authority. The query was prompted by the companies' broad business-activity classification.
1 min readOlin (OLN) and Huntsman (HUN) cleared a U.S. antitrust hurdle for their all-stock merger, expected to create a $12.5B chemicals company with $400M in cost synergies. The deal, targeting 1H 2027 completion, still needs regulatory approvals. OLN shares fell 32.2% and HUN dropped 8.6% over the past year.
3 min readOlin and Huntsman announced the expiration of the Hart-Scott-Rodino waiting period for their proposed merger. Huntsman, a global chemical manufacturer, reported 2025 revenues of approximately $6 billion. The merger's completion is subject to regulatory approvals and other conditions.
2 min readOlin (OLN) and Huntsman (HUN) announced the expiration of the HSR Act waiting period for their proposed merger, satisfying a key closing condition. Shareholders approved the transaction, but regulatory approvals are still required. Olin is a chemical and ammunition manufacturer, while Huntsman is a diversified chemical producer with 2025 revenues of $6 billion.
2 min readThe article highlights three U.S. small-cap stocks with recent insider buying: Parke Bancorp (PBHC), Anika Therapeutics (ANIK), and Huntsman (HUN). Parke Bancorp reported Q2 2026 net income growth, while Anika Therapeutics raised earnings guidance. Huntsman's chairman made significant share purchases amid a merger with Olin Corporation. All three companies are noted for potential undervaluation.
2 min readHuntsman and Olin have filed a Form II application in India for their planned merger, citing negligible overlap in the Indian market for epoxy-related chemicals and ethyleneamines. The companies are seeking antitrust clearance from India's competition regulator.
2 min readOlin (OLN) and Huntsman (HUN) shareholders approved their all-stock merger, with 97% and 99% approval respectively. The merger, announced in June, is expected to close in early 2027, creating OlinHuntsman Corp. The companies aim to form a value-focused chemicals firm with a vertically integrated platform.
2 min readHuntsman Corporation (NYSE:HUN) stockholders approved a merger agreement with Olin and an advisory proposal on executive compensation at a special meeting. The board recommended approval, and no adjournment vote was needed due to sufficient support. Final results will be filed with the SEC. Huntsman is a global specialty chemicals manufacturer.
2 min readHuntsman and Olin shareholders approved a merger, creating OlinHuntsman with expected $12.5B revenue and $12B market value. Olin shareholders will hold 54.5% equity, Huntsman 45.5%. The merger aims to leverage industrial synergies, with Olin providing chlorine gas to Huntsman's polyurethane production. Huntsman reported 2025 revenue of $5.683B, a 5.8% decline, and a net loss of $284M. The merger is expected to close in 2027.
2 min read
